ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
ProPhase Labs (NASDAQ: PRPH) has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The extension comes after the company failed to meet the requirement during the initial 180-day period ending June 24, 2025. ProPhase now has until December 22, 2025 to achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days to maintain its Nasdaq listing.
The extension was granted based on ProPhase meeting all other Capital Market initial listing requirements except the bid price requirement. If compliance is not achieved by the December deadline, Nasdaq will provide written notification of delisting. The company states this notice does not affect its business operations, SEC reporting requirements, or contractual obligations.
ProPhase Labs (NASDAQ: PRPH) ha ottenuto una proroga di 180 giorni da Nasdaq per rientrare nei requisiti minimi del prezzo di offerta di $1,00. La proroga è stata concessa dopo che la società non è riuscita a rispettare tale requisito nel periodo iniziale di 180 giorni terminato il 24 giugno 2025. ProPhase ha ora tempo fino al 22 dicembre 2025 per raggiungere un prezzo di chiusura di almeno $1,00 per azione per un minimo di 10 giorni lavorativi consecutivi, al fine di mantenere la quotazione su Nasdaq.
La proroga è stata concessa poiché ProPhase ha soddisfatto tutti gli altri requisiti iniziali di quotazione del mercato capitale, ad eccezione del requisito sul prezzo di offerta. Se la conformità non sarà raggiunta entro la scadenza di dicembre, Nasdaq invierà una notifica scritta di esclusione dalla quotazione. La società dichiara che tale avviso non influisce sulle sue operazioni commerciali, sugli obblighi di rendicontazione alla SEC o sugli impegni contrattuali.
ProPhase Labs (NASDAQ: PRPH) ha recibido una prórroga de 180 días por parte de Nasdaq para recuperar el cumplimiento del requisito mínimo de precio de oferta de $1.00. La prórroga se otorgó después de que la compañía no cumpliera con el requisito durante el período inicial de 180 días que finalizó el 24 de junio de 2025. ProPhase ahora tiene hasta el 22 de diciembre de 2025 para lograr un precio de cierre de al menos $1.00 por acción durante un mínimo de 10 días hábiles consecutivos para mantener su cotización en Nasdaq.
La prórroga se concedió porque ProPhase cumplió con todos los demás requisitos iniciales de listado del mercado de capitales, excepto el requisito del precio de oferta. Si no se logra el cumplimiento antes de la fecha límite de diciembre, Nasdaq enviará una notificación por escrito de exclusión. La compañía afirma que este aviso no afecta sus operaciones comerciales, los requisitos de informes ante la SEC ni sus obligaciones contractuales.
ProPhase Labs (NASDAQ: PRPH)는 최소 $1.00 입찰가 요건을 충족하기 위해 나스닥으로부터 180일 연장 기간을 받았습니다. 이 연장은 회사가 2025년 6월 24일에 종료된 최초 180일 기간 동안 요건을 충족하지 못한 후에 부여되었습니다. ProPhase는 이제 나스닥 상장을 유지하기 위해 최소 10거래일 연속으로 주당 최소 $1.00 종가를 달성할 때까지 2025년 12월 22일까지 기간이 연장되었습니다.
이 연장은 ProPhase가 입찰가 요건을 제외한 모든 초기 자본시장 상장 요건을 충족했기 때문에 승인되었습니다. 12월 마감일까지 준수가 이루어지지 않으면 나스닥은 상장 폐지에 대한 서면 통지를 제공합니다. 회사는 이 통지가 사업 운영, SEC 보고 의무 또는 계약상 의무에 영향을 미치지 않는다고 밝혔습니다.
ProPhase Labs (NASDAQ : PRPH) a obtenu une prolongation de 180 jours de la part de Nasdaq pour retrouver la conformité avec l'exigence minimale de prix d'offre de 1,00 $. Cette prolongation intervient après que la société n'a pas respecté cette exigence durant la période initiale de 180 jours se terminant le 24 juin 2025. ProPhase dispose désormais jusqu'au 22 décembre 2025 pour atteindre un cours de clôture d'au moins 1,00 $ par action pendant au moins 10 jours ouvrables consécutifs afin de conserver sa cotation sur Nasdaq.
La prolongation a été accordée car ProPhase a satisfait à toutes les autres exigences initiales de cotation sur le marché des capitaux, à l'exception de l'exigence de prix d'offre. Si la conformité n'est pas atteinte avant la date limite de décembre, Nasdaq enverra une notification écrite de radiation. La société précise que cet avis n'affecte pas ses opérations commerciales, ses obligations de reporting auprès de la SEC ni ses engagements contractuels.
ProPhase Labs (NASDAQ: PRPH) hat von der Nasdaq eine 180-tägige Verlängerung erhalten, um die Einhaltung der Mindestgebotspreisanforderung von 1,00 USD wiederherzustellen. Die Verlängerung wurde gewährt, nachdem das Unternehmen die Anforderung während des ursprünglichen 180-Tage-Zeitraums bis zum 24. Juni 2025 nicht erfüllt hatte. ProPhase hat nun bis zum 22. Dezember 2025 Zeit, einen Schlussgebotspreis von mindestens 1,00 USD pro Aktie für mindestens 10 aufeinanderfolgende Handelstage zu erreichen, um die Nasdaq-Notierung aufrechtzuerhalten.
Die Verlängerung wurde gewährt, da ProPhase alle anderen anfänglichen Kapitalmarkt-Listing-Anforderungen außer der Gebotspreisanforderung erfüllt hat. Sollte die Einhaltung bis zur Dezember-Frist nicht erreicht werden, wird Nasdaq eine schriftliche Mitteilung über die Delistung senden. Das Unternehmen erklärt, dass diese Mitteilung keine Auswirkungen auf seine Geschäftstätigkeiten, SEC-Berichtspflichten oder vertraglichen Verpflichtungen hat.
- Company received additional 180 days to regain compliance with Nasdaq requirements
- Company meets all other Nasdaq Capital Market listing requirements except bid price
- Stock price has remained below $1.00 for extended period
- Risk of potential delisting from Nasdaq if compliance not achieved by December 22, 2025
- Failed to regain compliance during initial 180-day period
Insights
ProPhase Labs received a second 180-day Nasdaq extension to meet the $1 minimum bid requirement, with delisting possible after December 22.
ProPhase Labs (PRPH) has secured an additional 180-day extension from Nasdaq to regain compliance with the exchange's minimum bid price requirement. This extension comes after the company failed to meet the requirement during its initial 180-day remediation period that expired on June 24, 2025.
The core issue is that PRPH's stock has been trading below the critical $1.00 threshold for an extended period. To maintain its Nasdaq listing, the company must now achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the new deadline of December 22, 2025.
This second extension indicates that ProPhase meets all other Nasdaq Capital Market listing requirements except for the share price criterion. Should the company fail to regain compliance by the December deadline, it would likely face delisting procedures, which could significantly impact stock liquidity and institutional ownership.
While management has not outlined specific remediation strategies in this announcement, companies in similar situations typically consider reverse stock splits to artificially increase share price. The continued non-compliance signals persistent market concerns about the company's performance and prospects, though management emphasizes this development doesn't affect business operations or SEC reporting requirements.
UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum
As previously announced, the Company received a written notification from Nasdaq dated December 26 2024, indicating that because the closing bid price of the Company's common shares for the previous 30 consecutive business days was below
As of the date hereof, the Company has not regained compliance with the Bid Price Requirement. Pursuant to the Extension Notice, the Company is eligible for an additional 180 calendar day period, or until December 22, 2025, to regain compliance with the Bid Price Requirement. To regain compliance, the Company's Class A ordinary shares must have a closing bid price of at least US
The Company intends to monitor the closing bid price of its common shares between now and December 22, 2025, and is considering its options to regain compliance with the Bid Price Requirement. The Company believes that the Extension Notice does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or its contractual obligations.
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
Forward-Looking Statements
Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.
The information contained in this press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The statements made herein reflect the Company’s current views with respect to potential business opportunities and are based on currently available information, assumptions, and expectations. These statements are not guarantees of future performance or outcomes and are subject to risks and uncertainties. Comparisons to other companies or transactions, such as the referenced sale of 23andMe to Regeneron, are provided solely for illustrative purposes and do not imply any specific valuation or outcome for Nebula or any potential transaction involving it. No assurance can be given that any transaction will be pursued or consummated.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
FAQ
What is the deadline for ProPhase Labs (PRPH) to regain Nasdaq compliance?
What must PRPH do to maintain its Nasdaq listing?
Why did Nasdaq grant PRPH an extension for compliance?
What happens if PRPH fails to meet Nasdaq's minimum bid requirement by December 2025?
Does the Nasdaq notice affect PRPH's business operations?
